1
EXHIBIT 10.33
UC Case Nos. [***]
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT FOR METHODS FOR [***]
THIS FIRST AMENDMENT TO LICENSE AGREEMENT (the "First Amendment") is
effective this 22nd day of June 1997 between The Regents of the University of
California, a California corporation with administrative headquarters at 000
Xxxxxxxx Xxxxx, 00xx Xxxxx, Xxxxxxx, Xxxxxxxxxx 00000-0000 ("The Regents"), and
Signal Pharmaceuticals, Inc., a California corporation with an address at 00000
Xxxxxxxx Xxxxxx Xxxx, Xxxxx 000, Xxx Xxxxx, Xxxxxxxxxx 00000 ("Licensee").
BACKGROUND
A. The Regents and Licensee entered into an agreement effective October 26, 1993
(UC Control No. 93-04-0786) which is entitled [***] (the "License Agreement");
B. The Regents and Licensee wish to amend the License Agreement to include
rights to The Regents' undivided interest in pending U.S. Patent Application No.
[***]. Rights granted in this First Amendment are limited to The Regents'
undivided interest because the patent application is the result of a
collaboration between The Regents and The University of Massachusetts Medical
Center (UMMC) and is jointly assigned to both institutions.
C. UMMC has filed conflicting patent applications, which could lead to
interferences with patent applications filed under UC Case No. [***] and
increase Licensee's patent prosecution costs under this license.
D. The Regents and Licensee also wish to amend the License Agreement to show
negotiated and agreed upon changes to the terms on sublicensing,
confidentiality, patent enforcement, place of manufacture for Licensed Products,
and dispute resolution.
U.C. AGREEMENT
CONTROL NUMBER
93-04-0786I
1
***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. Sections 200.80, 200.83 and 230.406
2
First Amendment to Exclusive License Agreement U.C. Control No. 93-04-0786
E. The parties wish to clarify and bring current the patents and patent
applications that are subject to this agreement, including the addition of
certain continuation-in-part applications.
F. As recited in Paragraph 6.5 of the License Agreement, if the Licensee is
unable to meet any of the dates set forth in Paragraph 6.4 of the License
Agreement, with regard to either the [***] Technologies or the [***]
Technologies, the parties shall in good faith re-establish a date or dates that
are reasonable under the then current circumstances. Since Signal has made
significant progress in the development of both the [***] Technologies and the
[***] Technologies, The Regents wishes to amend the License Agreement to extend
the due diligence dates recited in Paragraph 6.4 by [***] as requested by
Licensee.
Licensee and The Regents agree:
1. Paragraph 1. 1 of Article 1 (Definitions) of the License Agreement is
removed in its entirety and replaced with the following:
1.1 "Regents' Patent Rights" means The Regents' interest in subject
matter claimed in or covered by any of the following:
1.1.(1) Pending U.S. Patent Application Serial No. [***] entitled
"[***]", filed [***], [***] by [***] (UC Case [***]), which is a
continuation application to U.S. Patent Application [***] (UC Case
No. [***]);
1.1.(2) Pending U.S. Patent Application Serial [***] entitled
"[***]", filed [***] by [***] (UC Case [***]);
1.1.(3) U.S. Patent No. [***] entitled "[***] [***]", filed on [***]
by [***] (UC Case No. [***]);
1.1.(4) Pending U.S. Patent Application Serial No. [***] entitled
"[***]", filed [***] by [***] (UC Case No. [***]);
2
***Confidential Treatment Requested
3
First Amendment to Exclusive License Agreement U.C. Control No. 93-04-0786
1. 1. (5) U. S. Patent No. [***] entitled "[***]", filed [***] by
[***] (UC Case No. [***]);
1. 1. (6) U. S. Patent No. [***] entitled "[***]", filed on [***] by
[***] (UC Case No. [***]);
1. 1. (7) Pending U.S. Patent Application Serial No. [***] entitled
"[***]", filed [***] by [***] (UC Case No. [***]);
1.1.(8) Pending U.S. Patent Application Serial No. [***], entitled
"[***]", filed [***] by [***] (UC Case No. [***]);
1.1.(9) Pending U.S. Patent Application Serial No. [***], entitled
"[***]", filed [***] by [***] (UC Case No. [***]);
and continuing applications thereof including divisions and substitutions
but excluding continuation-in-part applications, except to the extent that
those continuation-in-part applications contain claims supported in the
original application; any patents issuing on said application or
continuing applications including reissues; and any corresponding foreign
applications or patents.
2. Paragraph 3.3 of Article 3 (Sublicensing) of the License Agreement is
removed in its entirety and replaced with the following:
3.3 Upon termination of this Agreement or reduction of its licenses to
non-exclusive, for any reason, The Regents shall accept assignment of
sublicenses, to the extent that it is not unreasonable for The Regents to
do so as a public entity and provided that:
(a) The Licensee was not in breach of this Agreement when entering
into the sublicense;
3
***Confidential Treatment Requested
4
First Amendment to Exclusive License Agreement U.C. Control No. 93-04-0786
(b) The sublicensee is not in breach of its sublicense agreement at
the time of termination of this Agreement; and
(c) The sublicensee acquires no rights from or obligations on the
part of The Regents other than those that are specifically granted
in this Agreement, and the sublicensee assumes all obligations to
The Regents required of Licensee by this Agreement, including past
due obligations existing at the time of assumption of the
sublicense, as well as any additional payments required by the
sublicense.
3. Paragraph 6.4 of Article 6 (Due Diligence) of the License Agreement is
removed in its entirety and replaced with the following:
[***]
6.4h reasonably fill the market demand for Licensed Products following
commencement of marketing at any time during the exclusive period of this
Agreement;
4
***Confidential Treatment Requested
5
First Amendment to Exclusive License Agreement U.C. Control No. 93-04-0786
then, subject to Paragraph 6.5, The Regents shall have the right and
option either to terminate this Agreement or to reduce the Licensee's
exclusive license to a nonexclusive license. This right, if exercised by
The Regents, supersedes the rights granted in Article 2 (Grant).
4. The fourth sentence of Paragraph 6.5 of the License Agreement which reads,
"The annual license maintenance fee shall begin to be payable in [***] for the
[***] Technologies, or [***] for the [***] Technologies, on the anniversary date
of the effective date hereof and shall continue until sales of the delayed
product begin," is removed and replaced with the following:
"The annual license maintenance fee shall begin to be payable in [***] for
the [***] Technologies, or [***] for the [***] Technologies, on the
anniversary date of the effective date hereof and shall continue until
sales of the delayed product begin. "
5. Paragraph 6.6 of Article 6 (Due Diligence) of the License Agreement is
removed in its entirety and replaced with the following:
6.6 Either party to this Agreement shall refer a dispute arising under
this Article to mediation prior to commencing litigation with the other
party under this Agreement. The mediation shall be conducted in accordance
with the rules of the Commercial Arbitration and Mediation Center for the
Americas.
6. Article 25 (Preference for United States Industry) of the License
Agreement is removed in its entirety and replaced with the following:
25.1 Because this Agreement grants the exclusive right to use or sell the
Inventions in the United States, the Licensee agrees that any products
sold in the U.S. embodying these Inventions or produced through the use
thereof will be manufactured substantially in the United States.
5
***Confidential Treatment Requested
6
First Amendment to Exclusive License Agreement U.C. Control No. 93-04-0786
7. Subparagraph 28.1(3) of Article 28 (Secrecy) of the License Agreement is
removed in its entirety and replaced with the following:
28.1(3) not to disclose Data to others (except to its employees, agents,
consultants, investors or collaborators who are bound to the Licensee by a
like obligation of confidentiality) without the express written
permission of the disclosing party, except that the Recipient shall not
be prevented from using or disclosing any of the Data:
(a) which the Recipient can demonstrate by written records was previously
known to it;
(b) which is now, or becomes in the future, public knowledge other than
through acts or omissions of the Recipient; or
(c) which is lawfully obtained by the Recipient from sources independent
of the disclosing party.
8. Licensee and The Regents recognize that the license granted in the License
Agreement to pending U.S. Patent Application No. [***] may be limited by
the outcome of an interference, if one is declared, between The Regents and
UMMC. The Licensee will, however, have a license under any rights remaining to
The Regents following any interference proceeding.
6
***Confidential Treatment Requested
7
First Amendment to Exclusive License Agreement U.C. Control No. 93-04-0786
9. Except as amended, modified and supplemented by the terms of this First
Amendment, the License Agreement shall remain in full force and effect in
accordance with its terms.
The parties have executed this FIRST AMENDMENT TO THE LICENSE AGREEMENT by their
respective and duly authorized officers, as evidenced by the signatures below.
SIGNAL PHARMACEUTICALS, INC. THE REGENTS OF THE UNIVERSITY
OF CALIFORNIA
By: /s/ XXXX XXXXXXXX By: /s/ XXXXXXX X. XXXXXXXXX
-------------------------------- ---------------------------------
(Signature) (Signature)
Name: /s/ XXXX XXXXXXXX Name:
------------------------------ -------------------------------
(Please Print) Xxxxxxx X. Xxxxxxxxx
Title: E.V.P. Title: Executive Director
Research Administration and
Technology Transfer
Date: 6/19/97 Date: 6/22/97
------------------------------ -------------------------------
Approved as to legal form: /s/ XXXXXX X. XXXXXXX 6/14/92
----------------------- -------
Xxxxxx X. Xxxxxxx, Attorney Date
Office of Technology Transfer
University of California
7
